other material
confidence high
sentiment neutral
materiality 0.50
Spero shareholders approve doubling authorized shares to 240M and 2026 equity plan
Spero Therapeutics, Inc.
- Authorized common shares increased from 120M to 240M via certificate of amendment filed June 23, 2026.
- 2026 Stock Incentive Plan approved; up to 12,895,866 shares may be issued under the plan.
- Directors Milind Deshpande, Ph.D. and Kathleen Tregoning reelected as Class III directors until 2029.
- PricewaterhouseCoopers LLP ratified as independent auditor for fiscal year 2026 with 99.5% votes for.
- Advisory vote on named executive officer compensation approved with ~96% of votes cast in favor.